Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Social vulnerability and hypoglycemia among patients with diabetes.

Waitman J, Caeiro G, Romero Gonzalez SA, Ré DP, Daghero A, Gonzalez CD, Umpierrez GE.

Endocrinol Diabetes Nutr. 2017 Feb;64(2):92-99. doi: 10.1016/j.endinu.2016.11.008. Epub 2017 Feb 9. English, Spanish.

PMID:
28440783
2.

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.

Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators.

N Engl J Med. 2017 Jan 5;376(1):32-40. doi: 10.1056/NEJMoa1611688. Epub 2016 Nov 13.

PMID:
27959717
3.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators.

N Engl J Med. 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.

4.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators.

N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.

5.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

6.

Pharmacologic Treatment of Obesity.

Isoldi KK, Aronne LJ, Waitman JA, Kumar RB.

In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2013 Feb 3.

7.

Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus.

Derumeaux G, Ernande L, Serusclat A, Servan E, Bruckert E, Rousset H, Senn S, Van Gaal L, Picandet B, Gavini F, Moulin P; REGULATE trial investigators.

PLoS One. 2012;7(6):e38273. doi: 10.1371/journal.pone.0038273. Epub 2012 Jun 19.

8.

Implantable gastric stimulator does not prevent the increase in plasma ghrelin levels that occurs with weight loss.

Korner J, Nandi A, Wright SM, Waitman J, McMahon DJ, Bessler M, Aronne LJ.

Obesity (Silver Spring). 2011 Oct;19(10):1935-9. doi: 10.1038/oby.2010.162.

9.

[Diabetes mellitus: current and future perspectives].

Waitman JN.

Rev Fac Cien Med Univ Nac Cordoba. 2010;67(2):71. Spanish. No abstract available.

PMID:
21450142
10.

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.

Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW; APPROACH Study Group.

Circulation. 2010 Mar 16;121(10):1176-87. doi: 10.1161/CIRCULATIONAHA.109.881003. Epub 2010 Mar 1.

11.

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.

Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators.

Int J Clin Pract. 2009 Sep;63(9):1395-406. doi: 10.1111/j.1742-1241.2009.02143.x. Epub 2009 Jul 15. Erratum in: Int J Clin Pract. 2010 Jan;64(2):277.

12.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.

Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.

13.

Gastric pacing is not enough: additional measures for an effective obesity treatment program.

Aronne LJ, Waitman JA.

Obes Surg. 2004 Sep;14 Suppl 1:S23-7. Review.

PMID:
15479586
14.

An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes.

Vongthavaravat V, Wajchenberg BL, Waitman JN, Quimpo JA, Menon PS, Ben Khalifa F, Chow WH; 125 Study Group.

Curr Med Res Opin. 2002;18(8):456-61.

PMID:
12564655
15.

Obesity surgery: pros and cons.

Waitman JA, Aronne LJ.

J Endocrinol Invest. 2002 Nov;25(10):925-8. Review. No abstract available.

PMID:
12508958
16.

Meperidine--a liability.

Waitman J, McCaffery M.

Am J Nurs. 2001 Jan;101(1):57-8. No abstract available.

PMID:
11211689
17.

[Glycosylated hemoglobins in the diabetic patient].

Waitman JN, Larrusse CA, Gallerano RH, Pugge HR, Mariano L, Luna Radulovich A.

Rev Fac Cien Med Univ Nac Cordoba. 1986;44(1):7-8. Spanish. No abstract available.

PMID:
3438557
18.

[Statistics of diabetic patients hospitalized in Córdoba Hospital].

Waitman JN, Ciani JG, Brutti NI, Mariano L, Gallerano RH.

Rev Fac Cien Med Univ Nac Cordoba. 1985;43(2):32-4. Spanish. No abstract available.

PMID:
3842534
19.

[Diabetes education. Its therapeutic importance].

Waitman JN, Ciani JG, Brutti NI, Mariano LV, Gallerano RH.

Rev Fac Cien Med Univ Nac Cordoba. 1984;42(1):47-8, 51-2. Spanish. No abstract available.

PMID:
6537609
20.

[Diabetes and carpal tunnel syndrome. Review and report of 3 cases].

Waitman JN, Ciani JG, Brutti NI, Larrusse CA, Gallerano RH.

Rev Fac Cien Med Univ Nac Cordoba. 1983;41(1):37-9. Spanish. No abstract available.

PMID:
6647981

Supplemental Content

Loading ...
Support Center